Gregory Covino - Biogen Insider

Biogen Inc -- USA Stock  

USD 317.25  0.26  0.080000%

Chief Accounting Officer, VP of Fin. and Controller

Mr. Gregory F. Covino was appointed as Interim Principal Financial Officer, Chief Accounting Officer, Vice President Finance of the Company., effective June 30, 2017. He currently serves as Chief Accounting Officer, Vice President Finance of Biogen Inc. Mr. Covino has served as the Companys Vice President and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporationrationration, a medical device company, as Vice President, Corporationrationrate Analysis and Control Executive since March 2010, having responsibility for the companys internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the companys international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrate Accounting from 1999 to 2002.
Age: 50  VP Since 2017      
617 679-2000  www.biogenidec.com
Covino has served as our Vice President, Finance and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporationrationrationration, a medical device company, as Vice President, Corporationrationrationrate Analysis and Control since March 2010, having responsibility for the company internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrationrate Accounting from 1999 to 2002. He received his B.S. in Business Administration from Bryant University.

Gregory Covino Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 15.3 % which means that it generated profit of $15.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 28.62 % meaning that it created $28.62 on every $100 dollars invested by stockholders.
The company currently holds 6.51 B in liabilities with Debt to Equity (D/E) ratio of 56.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biogen Inc has Current Ratio of 2.06 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. Biogen Inc (BIIB) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 7,350 people. Biogen is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Equity Valuation Now
   

Equity Valuation

Check real value of public entities based on technical and fundamental data
Hide  View All  Next  Launch Equity Valuation
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Inc to your portfolio

Top Management

Biogen Inc Leadership Team
Richard Mulligan, Director, Ph.D
Paul McKenzie, President, Ph.D
Michel Vounatsos, President, MBA
Sanjay Jariwala, President
George Scangos, CEO, Ph.D
Alfred Sandrock, President, Ph.D
Spyros ArtavanisTsakonas, President, Ph.D
Alexander Denner, Director, Ph.D
Douglas Williams, EVP
JeanPaul Kress, President
Eric Rowinsky, Director
Adriana Karaboutis, EVP
Kenneth Pietro, President
Adam Koppel, President, MBA
Stephen Sherwin, Director, Ph.D
Caroline Dorsa, Director
Michael Ehlers, President, Ph.D
Ginger Gregory, President
Susan Alexander, President
Catherine Steele, President
Paul Clancy, CFO, MBA
Steven Holtzman, President
Anirvan Ghosh, President, Ph.D
Nancy Leaming, Director
Lynn Schenk, Director
Brian Posner, Director
Gregory Covino, VP
Tony Kingsley, President, MBA
Anabella Villalobos, President, Ph.D
Stelios Papadopoulos, Chairman, Ph.D
John Cox, EVP, MBA
Robert Pangia, Director
Matt Griffiths, President

Stock Performance

Biogen Performance Indicators